Amphivena Therapeutics Inc., a private clinical stage immuno-oncology company developing T-cell engager therapeutics for cancer, announced the closing of a $62 million Series C financing.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Business Wirehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBusiness Wire2019-09-24 09:00:032019-09-24 12:58:13Amphivena Closes $62 Million Series C Financing